Reappraisal of the activity of morphazinamide against M. tuberculosis

Bravo, Teodoro Carrada; Ellard, G. A.; Mitchison, D.A.; Horsfall, P.A.L.

doi:10.1016/0041-3879(75)90054-9

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although no studies specifically tested this regimen it sits either in category RIF ED≥3 Pr6 D=6m or RIF ED≥3 Pr6 D>6m, the latter of which was the most efficacious in our network. RIF ED≥3 Pr6 D>6m contained two trialled regimens: (1) seven and a half months of INH, STM, RIF and PZA administered daily for the first month and a half and then intermittently (apart from the INH) and (2) 12 months of EMB, morphazinamide (a drug closely related to PZA with more unfavourable AE profile) 76 77 and RIF, administered daily.…”

Section: Discussionmentioning

confidence: 99%

What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis

Obach

et al. 2016

Thorax

View full text Add to dashboard Cite

IntroductionConsensus on the best treatment regimens for patients with isoniazid-resistant TB is limited; global treatment guidelines differ. We undertook a systematic review and meta-analysis using mixed-treatment comparisons methodology to provide an up-to-date summary of randomised controlled trials (RCTs) and relative regimen efficacy.MethodsOvid MEDLINE, the Web of Science and EMBASE were mined using search terms for TB, drug therapy and RCTs. Extracted data were inputted into fixed-effects and random-effects models. ORs for all possible network comparisons and hierarchical rankings for different regimens were obtained.Results12 604 records were retrieved and 118 remained postextraction, representing 59 studies—27 standalone and 32 with multiple papers. In comparison to a baseline category that included the WHO-recommended regimen for countries with high levels of isoniazid resistance (rifampicin-containing regimens using fewer than three effective drugs at 4 months, in which rifampicin was protected by another effective drug at 6 months, and rifampicin was taken for 6 months), extending the duration of rifampicin and increasing the number of effective drugs at 4 months lowered the odds of unfavourable outcomes (treatment failure or the lack of microbiological cure; relapse post-treatment; death due to TB) in a fixed-effects model (OR 0.31 (95% credible interval 0.12–0.81)). In a random-effects model all estimates crossed the null.ConclusionsOur systematic review and network meta-analysis highlight a regimen category that may be more efficacious than the WHO population level recommendation, and identify knowledge gaps where data are sparse.Systematic review registration numberPROSPERO CRD42014015025.

show abstract

Section: Discussionmentioning

confidence: 99%